

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 December 21; 23(47): 8263-8438



**REVIEW**

- 8263 Clinical epidemiology and disease burden of nonalcoholic fatty liver disease  
*Perumpail BJ, Khan MA, Yoo ER, Cholanckeril G, Kim D, Ahmed A*

**MINIREVIEWS**

- 8277 Obese children with fatty liver: Between reality and disease mongering  
*Ranucci G, Spagnuolo MI, Iorio R*
- 8283 Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities  
*Lippi G, Sanchis-Gomar F*

**ORIGINAL ARTICLE****Basic Study**

- 8291 Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing  
*Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A, Knuutila S*
- 8300 Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease  
*Senhaji N, Nadifi S, Zaid Y, Serrano A, Rodriguez DAL, Serbati N, Karkouri M, Badre W, Martín J*
- 8308 Effects of initiating time and dosage of *Panax notoginseng* on mucosal microvascular injury in experimental colitis  
*Wang SY, Tao P, Hu HY, Yuan JY, Zhao L, Sun BY, Zhang WJ, Lin J*
- 8321 Fructo-oligosaccharide intensifies visceral hypersensitivity and intestinal inflammation in a stress-induced irritable bowel syndrome mouse model  
*Chen BR, Du LJ, He HQ, Kim JJ, Zhao Y, Zhang YW, Luo L, Dai N*
- 8334 Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model  
*Sang L, Wang XM, Xu DY, Sang LX, Han Y, Jiang LY*
- 8345 Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer  
*Yang F, Liu DY, Guo JT, Ge N, Zhu P, Liu X, Wang S, Wang GX, Sun SY*

**Case Control Study**

- 8355 Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity  
*Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H*

**Retrospective Study**

- 8367 Association between white opaque substance under magnifying colonoscopy and lipid droplets in colorectal epithelial neoplasms  
*Kawasaki K, Eizuka M, Nakamura S, Endo M, Yanai S, Akasaka R, Toya Y, Fujita Y, Uesugi N, Ishida K, Sugai T, Matsumoto T*
- 8376 Nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival of patients with gastric neuroendocrine neoplasms  
*Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH, Huang CM*
- 8387 Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis  
*Xiang JX, Hu LS, Liu P, Tian BY, Su Q, Ji YC, Zhang XF, Liu XM, Wu Z, Lv Y*

**Clinical Trials Study**

- 8395 First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease  
*Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group*

**Observational Study**

- 8405 Rate of adverse events of gastroduodenal snare polypectomy for non-flat polyp is low: A prospective and multicenter study  
*Córdova H, Argüello L, Loras C, Naranjo Rodríguez A, Riu Pons F, Gornals JB, Nicolás-Pérez D, Andújar Murcia X, Hernández L, Santolaria S, Leal C, Pons C, Pérez-Cuadrado-Robles E, García-Bosch O, Papo Berger M, Ulla Rocha JL, Sánchez-Montes C, Fernández-Esparrach G*

**META-ANALYSIS**

- 8415 Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: A meta-analysis  
*Hágendorn R, Farkas N, Vincze Á, Gyöngyi Z, Csupor D, Bajor J, Erőss B, Csécei P, Vasas A, Szakács Z, Szapáry L, Hegyi P, Mikó A*

**CASE REPORT**

- 8426 Disabling portosystemic encephalopathy in a non-cirrhotic patient: Successful endovascular treatment of a giant inferior mesenteric-caval shunt *via* the left internal iliac vein  
*de Martinis L, Groppelli G, Corti R, Moramarco LP, Quaretti P, De Cata P, Rotondi M, Chiovato L*
- 8432 Wernicke encephalopathy in a patient after liver transplantation: A case report  
*Xie B, Si ZZ, Tang WT, Qi HZ, Li T*

**LETTERS TO THE EDITOR**

- 8437 Silymarin: An option to treat non-alcoholic fatty liver disease  
*Colica C, Boccuto L, Abenavoli L*

## ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Yoshihisa Takahashi, MD, Associate Professor, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan

## AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

## INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports<sup>®</sup> cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29<sup>th</sup> among 79 journals in gastroenterology and hepatology (quartile in category Q2).

## FLYLEAF

## I-IX Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Yan Huang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*  
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

EDITORS-IN-CHIEF  
**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS  
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE  
Jin-Lei Wang, Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLISHER  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE  
December 21, 2017

COPYRIGHT  
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS  
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>

## Retrospective Study

# Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis

Jun-Xi Xiang, Liang-Shuo Hu, Peng Liu, Bo-Yan Tian, Qing Su, Yi-Chun Ji, Xu-Feng Zhang, Xue-Min Liu, Zheng Wu, Yi Lv

Jun-Xi Xiang, Liang-Shuo Hu, Bo-Yan Tian, Qing Su, Yi-Chun Ji, Xu-Feng Zhang, Xue-Min Liu, Zheng Wu, Yi Lv, Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China

Jun-Xi Xiang, Liang-Shuo Hu, Peng Liu, Xu-Feng Zhang, Xue-Min Liu, Yi Lv, Regenerative Medicine and Surgery Engineering Research Center of Shaanxi Province, Xi'an 710061, Shaanxi Province, China

ORCID number: Jun-Xi Xiang (0000-0002-7772-3261); Liang-Shuo Hu (0000-0001-8288-592X); Peng Liu (0000-0002-7951-9555); Bo-Yan Tian (0000-0002-8806-138X); Qing Su (0000-0003-0358-2221); Yi-Chun Ji (0000-0003-4192-8051); Xu-Feng Zhang (0000-0002-7908-1645); Xue-Min Liu (0000-0002-4489-9439); Zheng Wu (0000-0002-7102-9543); Yi Lv (0000-0002-7104-2414).

**Author contributions:** Xiang JX analyzed the data and drafted the manuscript; Hu LS provided analytical oversight; Liu P and Tian BY offered the technical support; Su Q and Ji YC collected the data; Zhang XF and Liu XM revised the manuscript for important intellectual content; Wu Z provided administrative support; Lv Y designed and supervised the study; all authors have read and approved the final version to be published.

**Supported by the National Natural Science Foundation of China, No. 81501608.**

**Institutional review board statement:** The entire study was carried out in strict accordance with protocols approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (Permit Number: 2017-017).

**Informed consent statement:** This study received an informed consent waiver from our Institutional Review Board due to minimal risk to study subjects.

**Conflict-of-interest statement:** The authors have declared that no conflicts of interest exist.

**Data sharing statement:** No additional data available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Yi Lv, MD, PhD, Professor, Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, No. 277, West Yanta Road, Xi'an 710061, Shaanxi Province, China. [luyi169@126.com](mailto:luyi169@126.com)  
Telephone: +86-29-85323902  
Fax: +86-29-85323904

Received: October 18, 2017  
Peer-review started: October 18, 2017  
First decision: November 8, 2017  
Revised: November 11, 2017  
Accepted: November 27, 2017  
Article in press: November 27, 2017  
Published online: December 21, 2017

## Abstract

### AIM

To investigate the impact of cigarette smoking on the recurrence rate and recurrence-free survival in patients with hyperlipidemic acute pancreatitis (HLAP).

### METHODS

A total of 863 patients were admitted to our hospital for acute pancreatitis (AP) from January 2013 to March



2016, of whom 88 diagnosed with HLAP were enrolled in this retrospective study. Demographic data, medical history, previous episodes of pancreatitis, consumption of alcohol and cigarettes, as well as biochemical and hematological data were carefully recorded for univariate and multivariate analyses. During follow-up, the information on current smoking status and recurrent AP was gathered. Recurrence-free survival (RFS) was calculated using the Kaplan-Meier method, and the differences between groups were compared using the log-rank test.

### RESULTS

No significant differences were observed between the three groups in age or medical history of hyperlipidemia, fatty liver, diabetes mellitus, hypertension, or AP. The current smokers had a remarkably higher recurrence rate and a greater incidence of repeated episodes of AP (50.0% and 77.8%, respectively) than non-smokers (9.8% and 39.0%), and these two percentages were reduced to 9.1% and 36.4% for patients who gave up smoking. The median follow-up time was 13.5 mo and HLAP recurred after hospital discharge in 23 (26.1%) patients. Multivariate analysis identified current smoking (HR = 6.3,  $P = 0.020$ ) as an independent risk factor contributing to HLAP recurrence. Current smokers had significantly worse RFS than non-smokers (23 mo *vs* 42 mo), but no significant difference was documented between ex-smokers (34 mo) and non-smokers. The RFS was not significantly different between light and heavy smokers.

### CONCLUSION

Smoking is associated with worse RFS and an increased rate of HLAP recurrence. Continued smoking correlates with a compromised survival and smoking cessation should be recommended.

**Key words:** Acute pancreatitis; Hyperlipemia; Smoking; Recurrence; Epidemiology

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This present study retrospectively enrolled hyperlipidemic acute pancreatitis (HLAP) patients in a large regional central hospital and revealed that cigarette smoking was associated with worse recurrence-free survival and an increased rate of HLAP recurrence. For smokers, continued smoking might be strongly correlated with HLAP recurrence and compromised survival. Therefore, smoking cessation should be strongly recommended.

Xiang JX, Hu LS, Liu P, Tian BY, Su Q, Ji YC, Zhang XF, Liu XM, Wu Z, Lv Y. Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis. *World J Gastroenterol* 2017; 23(47): 8387-8394 Available from: URL: <http://www.wjgnet.com>

## INTRODUCTION

Acute pancreatitis (AP) is a potentially life-threatening acute inflammatory condition of the pancreas with high morbidity and mortality<sup>[1]</sup>. It is widely believed that the most common etiologies of AP are gallstone disease and alcohol abuse. Currently, 12%-20% of patients with AP have previous hypertriglyceridemia, which has become a well-recognized etiology<sup>[2-4]</sup>. Hyperlipidemic acute pancreatitis (HLAP) is a form of AP occurring in the presence of severe hypertriglyceridemia and in the absence of other causes<sup>[5]</sup>. Some researchers even report hypertriglyceridemia as the underlying cause in more than half of all gestational pancreatitis cases<sup>[6]</sup>. Numerous studies have suggested that compared with other types of pancreatitis, HLAP is associated with more complications, a longer course of disease, and a higher recurrence rate<sup>[7]</sup>.

The exact pathophysiology of HLAP is not entirely certain. At present, it is believed that HLAP is related to injury in the pancreatic tissue (including acinar cells and pancreatic ducts) and microcirculation disturbance caused by free fatty acids (FFAs) that are produced by the pancreatic lipase, which catalyzes decomposition of triglycerides<sup>[5]</sup>. The resulting ischemia creates an acidic environment, which further triggers FFAs toxicity. In this way, inflammation can be initiated and amplified within the pancreas. Earlier studies found that cigarette smoking was independently associated with pancreatic cancer and chronic pancreatitis (CP) by leading to pancreatic calcification and abnormal secretion of the pancreatic ducts<sup>[8-10]</sup>. Notably, some recent studies identified that smoking was significantly associated with non-biliary AP instead of biliary AP<sup>[11,12]</sup>, indicating different pathophysiological mechanisms for these subtypes. However, whether cigarette smoking has any long-term impact on HLAP recurrence has not yet been investigated. Because the nicotine in tobacco can cause lipid metabolism disturbance and oxidative stress and further increase blood viscosity and microcirculation dysfunction in the pancreas<sup>[13]</sup>, it is reasonable to hypothesize that smoking may be associated with the high recurrence rate of HLAP.

This present study retrospectively enrolled HLAP patients treated at a large regional central hospital. The impact of cigarette smoking on recurrence rate and recurrence-free survival (RFS) in HLAP patients was investigated.

## MATERIALS AND METHODS

### Patients and diagnosis

A total of 863 patients were admitted to our hospital

for AP from January 2013 to March 2016, of whom 90 were hospitalized at least twice. Among these patients, those with biliary pancreatitis, alcoholic pancreatitis, and other causes were excluded from the study. The remaining 88 patients identified with HLAP were enrolled. The diagnosis of HLAP was made if patients had AP in the presence of serum total triglyceride (TG) > 11.3 mmol/L (1000 mg/dL), or had a serum TG level of 5.65 to 11.3 mmol/L accompanied by chylous serum after excluding other known risk factors for AP. The diagnosis of AP requires at least two of the following three features: acute upper abdominal pain often radiating through to the back, serum amylase and/or lipase levels  $\geq$  three times the upper limit of normal, and evidence of pancreatitis upon abdominal imaging<sup>[14]</sup>. The work described was carried out in accordance with The Code of Ethics of the World Medical Association. This research was approved by the Ethics Committees of the First Affiliated Hospital of Medical College, Xi'an Jiaotong University.

#### **Tobacco and alcohol exposure assessment**

Data on tobacco exposure were obtained from the baseline questionnaire and telephone follow-up. All patients were asked if they smoke regularly and, if so, for how many years they had smoked and the average number of cigarettes they smoked per day. Smoking data included smoking pack-years (PY, packages of cigarettes smoked per day multiplied by the number of years for which the individual has smoked). Smoking status was defined as non-smoker (<100 cigarettes during lifetime), ex-smoker, and current smoker. An ex-smoker was defined as one who had quit smoking for more than 6 mo before the end of follow-up after being discharged from the hospital. A current smoker was defined as one who smoked at least 1 cigarette per day for over 1 year and continued to smoke within 1 year prior to follow-up. Tobacco exposure was characterized as none, light smoker ( $0 < \text{PY} < 10$ ), and heavy smoker ( $\text{PY} \geq 10$ )<sup>[15,16]</sup>. Since alcohol and smoking are often linked behaviors<sup>[17]</sup>, there are questions about the independent influence of smoking. Therefore, exposure of alcohol was also investigated and taken into consideration. In accordance with previous guidelines, a high drinker was defined as one who has drunk at least 40 g/d (20 g/d for female) for over 5 years. Smokers and alcohol abusers were routinely encouraged to give up these bad habits.

#### **Treatment and follow-up**

All the patients were treated with comprehensive routine therapy, including restriction of oral intake, fluid expansion, parenteral nutrition, analgesia, proton pump inhibitor administration, inhibition of pancreatic enzyme secretion, antibiotics, early enteral nutrition, and plasma exchange, if needed<sup>[18]</sup>.

The information on demographic data, history of

hypertriglyceridemia, fatty liver, diabetes, hypertension, previous episodes of pancreatitis, consumption of alcohol and cigarettes, as well as biochemical and hematological data were carefully recorded at admission. During follow-up, we gathered information on current smoking status and recurrent AP. Repeated episodes were defined as patients who were diagnosed with AP more than twice during their lifetime. To avoid recurrence, all patients were counseled to continue dietary fat restriction after treatment. Lipid lowering agents were used for patients when necessary.

#### **Statistical analysis**

Statistical analyses were performed with the SPSS 21.0 software package (SPSS Inc., Chicago, IL, United States). Continuous variables are expressed as the mean  $\pm$  SE, and comparisons between groups were performed using non-parametric tests, the *t*-test, or ANOVA, as appropriate. Categorical variables were compared between groups using the  $\chi^2$  test or Fisher's exact test. RFS was calculated using the Kaplan-Meier method, and the differences between groups were compared using the log-rank test. Risk factors for the recurrence of HLAP were analyzed by univariate analysis first, and those with  $P < 0.20$  and possible clinical effect were included in multivariate analysis using a Cox proportional hazards model. A  $P$  value < 0.05 was considered statistically significant. The statistical methods and results of this study were reviewed by a biostatistician (Qian Li, PhD) at Xi'an Jiaotong University.

## **RESULTS**

Of the 88 patients with HLAP who were enrolled and analyzed (66 men and 22 women with a mean age of  $40.9 \pm 1.1$  year), 36 and 11 patients were documented as current smokers and ex-smokers, respectively, while 41 patients had no cigarette smoking history. The characteristics of the patients in the three groups are shown in Table 1. No significant differences were observed between the three groups in age or medical history of hyperlipemia, fatty liver, diabetes mellitus, hypertension, or AP. Of the current smokers, 55.6% had a history of AP, which was significantly higher than that of non-smokers (31.7%). Cigarette smoking patients were more likely to have concomitant alcohol abuse than non-smokers ( $P = 0.037$ ), and more male patients than females tended to smoke. Biochemical tests of serum TG, cholesterol (CHOL), amylase, lipase, and calcium levels were not significantly different between these groups, and nor were the leukocyte and platelet counts. Patients who currently or previously smoked had higher systemic inflammatory response syndrome (SIRS) proportions and bedside index for severity in acute pancreatitis (BISAP) scores than non-smokers, but the differences were not significant.

**Table 1** Clinical characteristics of the hyperlipidemic acute pancreatitis patients

Clinical parameter	Non-smokers No. or mean	Current-smokers No. or mean	Ex-smokers No. or mean	P value
N	41	36	11	
Age (yr)	42.7 ± 2.0	39.1 ± 1.2	40.0 ± 2.2	0.446
Gender (M/F)	20/21	36/0	10/1	< 0.001 <sup>a</sup>
Heavy alcohol drinking	4	12	2	0.037 <sup>a</sup>
Smoking pack-years	0	13.5 ± 2.2	7.8 ± 2.9	< 0.001 <sup>a</sup>
History of hyperlipemia	39	30	8	0.084
History of fatty liver	16	15	4	0.943
History of diabetes mellitus	10	14	5	0.258
History of hypertension	8	3	2	0.364
History of AP	13	20	3	0.065 <sup>a</sup>
Leukocyte (× 10 <sup>9</sup> /L)	12.5 ± 0.5	13.1 ± 0.7	12.3 ± 1.1	0.506
Platelet count (× 10 <sup>9</sup> /L)	185.2 ± 11.8	171.7 ± 8.2	175.6 ± 20.1	0.680
Serum TG (mmol/L)	18.3 ± 1.7	15.1 ± 1.5	17.1 ± 2.9	0.358
Serum CHOL (mmol/L)	9.0 ± 0.6	8.4 ± 0.6	8.0 ± 0.8	0.316
Serum amylase (U/L)	569.3 ± 104.5	507.7 ± 111.4	629.8 ± 121.9	0.270
Serum lipase (U/L)	1297.1 ± 228.1	874.1 ± 170.2	1214.4 ± 582.0	0.406
Serum calcium (mmol/L)	2.0 ± 0.04	2.1 ± 0.04	2.0 ± 0.08	0.197
SIRS	17	17	8	0.182
BISAP score	0.8 ± 0.1	0.8 ± 0.2	1.4 ± 0.3	0.224
Hospitalization (d) <sup>1</sup>	10.9 ± 0.8	8.6 ± 0.7	11.9 ± 1.6	0.015 <sup>a</sup>
Recurrence of AP	4	18	1	< 0.001 <sup>a</sup>
Repeated episodes of AP	16	28	4	0.001 <sup>a</sup>

<sup>a</sup>*P* < 0.05, current *vs* non-smokers; <sup>1</sup>Exclude those discharged without medical advice or transferred to a different hospital. AP: Acute pancreatitis; TG: Total triglyceride; CHOL: Cholesterol; SIRS: Systemic inflammatory response syndrome; BISAP: Bedside index for severity in acute pancreatitis.

In addition, current smokers had a remarkably higher recurrence rate and a greater incidence of repeated episodes of AP (50.0% and 77.8%, respectively) than non-smokers (9.8% and 39.0%, respectively). It is worth noting that these two percentages were reduced to 9.1% and 36.4% for patients who gave up smoking after being discharged from the hospital.

The median follow-up time was 13.5 mo (2-42 mo) by September 2016. HLAP recurred after discharge from the hospital in 23 (26.1%) patients. To investigate the risk factors contributing HLAP recurrence, we examined 19 potential variables and analyzed them by univariate analysis, as shown in Table 2. Univariate analysis identified that smoking history and smoking pack-years were risk factors associated with higher HLAP recurrence. Specifically, current smoking was a risk factor relative to non-smoking (HR = 5.1, 95%CI: 1.7-15.2, *P* = 0.003). Smoking PY < 10 was a protective factor relative to PY ≥ 10 (HR = 0.4, 95%CI: 0.2-0.9, *P* = 0.035). Additionally, the following three variables had a *P* value < 0.20: gender (*P* = 0.168), history of hyperlipemia (*P* = 0.141), and history of AP (*P* = 0.117). When introducing the five variables with *P* value < 0.20 in univariate analysis into multivariate analysis using a Cox proportional hazards model, we identified current smoking (HR = 6.3, 95%CI: 1.3-29.8, *P* = 0.020) as an independent risk factor contributing to HLAP recurrence (Table 3).

During follow-up, four non-smoker patients, one ex-smoker patient, and 18 current smoker patients experienced AP recurrence with different RFS time. Figure 1 shows the Kaplan-Meier curves for RFS of

non-, ex-, and current smokers. The median RFS time in non-smokers, ex-smokers, and current smokers was 42 mo, 34 mo, and 23 mo, respectively (*P* = 0.002). Current smokers had significantly worse RFS than non-smokers (*P* = 0.001), but no significant difference in RFS was documented between ex-smokers and non-smokers (*P* = 0.962). Kaplan-Meier curves for RFS in non-smokers (PY = 0), light smokers (0 < PY < 10), and heavy smokers (PY ≥ 10) are shown in Figure 2. The median RFS of non-smokers, light smokers, and heavy smokers was 42 mo, 23 mo, and 30 mo, respectively, indicating that the RFS was significantly worse in smokers than in non-smokers (*P* = 0.014). However, the RFS was not significantly different between light and heavy smokers (*P* = 0.749).

## DISCUSSION


In the present study, univariate and multivariate analyses identified that cigarette smoking status is an independent risk factor contributing to the recurrence of HLAP<sup>[19]</sup>. To the best of our knowledge, this is the first study evaluating the influence of cigarette smoking on HLAP recurrence. A recent comprehensive study analyzed 2810 patients (1065 with gallstone-related AP, 1222 with non-gallstone related AP, and 523 with recurrent AP/CP) and demonstrated that cigarette smoking was associated with non-gallstone-related AP and recurrent AP/CP<sup>[12]</sup>. Unfortunately, this study did not evaluate any correlation between cigarette smoking and HLAP recurrence. As non-gallstone-related AP was a broad category including various



**Table 2** Univariate analysis of risk factors for recurrence of hyperlipidemic acute pancreatitis

Variable	n	Number of recurrence	HR (95%CI)	P value
Age ( $\leq 40$ / $> 40$ , yr)	46/42	14/9	0.7 (0.3-1.6)	0.417
Gender (M/F)	66/22	20/3	2.4 (0.7-7.9)	0.168
Heavy alcohol drinking (Y/N)	18/70	6/17	1.4 (0.5-3.5)	0.507
Smoking history (Y/N)	47/41	19/4	4.3 (1.4-12.5)	0.009
Non-smokers	41	4	1 (ref.)	1 (ref.)
Current-smokers	36	18	5.1 (1.7-15.2)	0.003
Ex-smokers	11	1	1.1 (0.1-9.5)	0.959
Smoking pack-years ( $> 0$ but $< 10$ / $\geq 10$ )	64/24	11/12	0.4 (0.2-0.9)	0.035
0	41	4	1 (ref.)	1 (ref.)
0 < PY < 10	23	7	3.8 (1.1-13.1)	0.032
$\geq 10$	24	12	4.6 (1.5-14.2)	0.009
History of hyperlipemia (Y/N)	77/11	18/5	0.5 (0.2-1.3)	0.141
History of fatty liver (Y/N)	35/53	9/14	1.0 (0.4-2.2)	0.917
History of diabetes mellitus (Y/N)	29/59	10/13	1.7 (0.7-3.9)	0.208
History of hypertension (Y/N)	13/75	2/21	0.7 (0.2-2.9)	0.585
History of AP (Y/N)	36/52	13/10	1.9 (0.8-4.4)	0.117
Leukocyte ( $< 10$ / $\geq 10$ , $\times 10^9$ /L)	23/65	5/18	0.6 (0.2-1.7)	0.379
Platelet count ( $< 100$ / $\geq 100$ , $\times 10^9$ /L)	4/84	1/22	0.8 (0.1-5.7)	0.790
Serum TG ( $\leq 11.3$ / $> 11.3$ , mmol/L)	32/56	7/16	0.9 (0.4-2.2)	0.813
Serum CHOL ( $\leq 5.5$ / $> 5.5$ , mmol/L)	16/72	4/19	1.0 (0.3-2.8)	0.934
Serum amylase ( $< 540$ / $\geq 540$ , U/L)	62/26	18/5	1.6 (0.6-4.4)	0.335
Serum lipase ( $< 600$ / $\geq 600$ , U/L) <sup>1</sup>	31/34	8/9	0.6 (0.2-1.5)	0.273
Serum calcium ( $< 2.0$ / $\geq 2.0$ , mmol/L)	28/60	8/15	1.0 (0.4-2.3)	0.918
SIRS (Y/N)	42/46	11/12	1.1 (0.5-2.4)	0.858
BISAP score ( $< 2$ / $\geq 2$ )	69/19	19/4	1.3 (0.5-3.9)	0.610

<sup>1</sup>Data of the parameter in 65 of patients were available. AP: Acute pancreatitis; TG: Total triglyceride; CHOL: Cholesterol; SIRS: Systemic inflammatory response syndrome; BISAP: Bedside index for severity in acute pancreatitis; HR: Hazard ratio; CI: Confidence interval.



No. of patients at risk								
Non-smokers	41	39	28	19	12	7	3	1
Current smokers	36	33	21	15	13	11	5	1
Ex-smokers	11	11	6	4	2	1	-	-

**Figure 1** Kaplan-Meier curves for the recurrence-free survival of non-, ex-, and current smokers.

causes and pathogeneses, it was difficult to analyze the pathophysiologic mechanism of cigarette smoking leading to recurrent HLAP. The most significant difference between the study by Setiawan *et al.*<sup>[12]</sup> and ours is that our study takes HLAP into consideration as a specific disease to evaluate the effects of cigarette smoking on HLAP recurrence.

Notably, current smokers appeared to be associated with a higher recurrence rate and a greater incidence


of repeated episodes of AP. In addition, the RFS was significantly worse in smokers than in non-smokers. However, the RFS was not significantly different between light and heavy smokers. This finding implied that cigarette smoking might contribute to HLAP recurrence but not in a dose- or duration-dependent manner; however, this could not be fully demonstrated in the present study due to short follow-up period and the small number of patients enrolled. Rebours *et al.*<sup>[9]</sup> demonstrated in their study that alcoholic CP occurred earlier at a 20-pack-year threshold, and that patients had more calcifications. Similar results were observed in other research<sup>[8,11,20]</sup> with regard to CP or AP. Therefore, the importance of smoking in the recurrence of different AP cases might differ. Whether the level of tobacco exposure influences HLAP recurrence and RFS needs to be further evaluated.

Interestingly, ex-smokers who had quit smoking for at least 6 mo after discharge from the hospital had a significant advantage with regard to the recurrence rate and RFS compared to current smokers in the present study. Univariate and multivariate analyses also demonstrated that current smoking was an independent risk factor contributing to HLAP recurrence. Therefore, lifestyle modifications are a key feature in the long-term management of HLAP<sup>[21,22]</sup>. Due to a possible increase in recurrence rate related to smoking, doctors should always strongly suggest that the patient quit smoking once HLAP has been diagnosed. Moreover, current smokers had a higher

**Table 3** Multivariate analysis of risk factors for recurrence of hyperlipidemic acute pancreatitis

Variable	Hazard ratio	95%CI	P value
Gender (Male)	0.5	0.1-3.0	0.449
Smoking history (Current)	6.3	1.3-29.8	0.020
Smoking pack-years ( $\geq 10$ )	1.0	0.4-2.7	0.969
History of hyperlipemia (Yes)	0.7	0.2-1.8	0.435
History of AP (Yes)	1.4	0.6-3.3	0.422

AP: Acute pancreatitis; CI: Confidence interval.



No. of patients at risk

PY = 0	41	39	28	19	12	7	3	1
0 < PY < 10	23	22	10	7	4	2	-	-
PY $\geq 10$	24	22	17	12	11	10	5	1

**Figure 2** Kaplan-Meier curves for the recurrence-free survival of non-, light, and heavy smokers.

proportion of concomitant alcohol abuse than non- & ex-smokers in our cohort. We also entered "high alcohol drinking" as a potential variable influencing HLAP recurrence<sup>[23]</sup>. Although there were no data indicating a potential influence of high alcohol consumption on HLAP recurrence, it was recognized as a synergistic factor with smoking for AP occurrence and a negative prognostic factor for AP survival<sup>[3,24,25]</sup>. However, only a small sample of alcohol drinkers were enrolled in our study since alcohol drinking is not as common among the Chinese population as in Western populations, which might contribute to bias in this data analysis.

Several studies have shown unique molecular characteristics and behavior patterns of pancreatic cancer related to tobacco use. However, the mechanism by which cigarette smoking promotes HLAP recurrence remains unknown. Some experimental and clinical studies indicated that cigarette smoke aggravates pancreatic acinar cell injury and pancreatic calcification by increasing oxidative stress and the production of pro-inflammatory cytokines<sup>[8,20,26,27]</sup>. Nicotine, the main poisonous element of tobacco, might accumulate significantly in the pancreas and participate in regulating lipid peroxidation, resulting in

HLAP and HLAP recurrence.

There are several limitations in our present study. First, measurement error in self-reported tobacco use is possible and may have led to some degrees of nondifferential misclassification of exposure. Second, more-detailed classification is needed to clarify the potential dose- and duration-dependent correlation between cigarette smoking and HLAP. Finally, the number of cases within our exposure categories by pancreatitis type is small, and long-term follow-up is needed.

In the present study, we found that cigarette smoking was associated with worse RFS and an increased recurrence rate of HLAP. For smokers, continued smoking might be strongly correlated with HLAP recurrence and compromised survival. Therefore, smoking cessation should be strongly recommended. Future studies are needed to clarify possible changes in the metabolic and molecular characteristics of HLAP related to tobacco use and to determine whether these changes contribute to disease recurrence.

## ARTICLE HIGHLIGHTS

### Research background

Hyperlipidemic acute pancreatitis (HLAP) is a form of AP occurring in the presence of severe hypertriglyceridemia and in the absence of other causes. The exact pathophysiology of HLAP is not entirely certain. It is believed that HLAP is related to pancreatic tissue injury and microcirculation disturbance caused by free fatty acids. Some recent studies identified that smoking was significantly associated with non-biliary AP instead of biliary AP, but whether cigarette smoking has any long-term impact on HLAP recurrence has not yet been investigated. This is the first study evaluating the influence of cigarette smoking on HLAP recurrence.

### Research motivation

Authors performed this study to better understand the relationship between cigarette smoking and HLAP recurrence, as well as the pathophysiologic mechanism of recurrent HLAP.

### Research objectives

The main objective of this study was to investigate the impact of cigarette smoking on the recurrence rate and recurrence-free survival in HLAP. The authors found that cigarette smoking was associated with worse RFS and an increased recurrence rate of HLAP. These findings provide references for further clarifying the mechanism of HLAP.

### Research methods

A total of 88 patients diagnosed with HLAP were enrolled in this retrospective study. Demographic data, medical history, previous episodes of pancreatitis, consumption of alcohol and cigarettes, as well as biochemical and hematological data were carefully recorded for univariate and multivariate analyses. During follow-up, the information on current smoking status and recurrent AP was gathered. Recurrence-free survival was calculated using the Kaplan-Meier method, and the differences between groups were compared using the log-rank test.

### Research results

Current smokers had a remarkably higher recurrence rate and a greater incidence of repeated episodes of AP than non-smokers, and these two percentages were reduced to 9.1% and 36.4% for patients who gave up smoking. The median follow-up time was 13.5 mo. Multivariate analysis identified current smoking as an independent risk factor contributing to HLAP

recurrence. Current smokers had significantly worse RFS than non-smokers, but no significant difference was documented between ex-smokers and non-smokers.

### Research conclusions

In the present study, the authors found that cigarette smoking was associated with worse RFS and an increased recurrence rate of HLAP. For smokers, continued smoking might be strongly correlated with HLAP recurrence and compromised survival. Smoking cessation for at least 6 mo would lead to a significant advantage in recurrence rate and RFS compared to current smokers.

### Research perspectives

The study revealed that smoking is associated with worse RFS and higher recurrence rate of HLAP. Besides, smoking cessation for at least 6 mo would lead to a significant advantage in recurrence rate and RFS compared to current smokers. For the future research, more detailed classification is needed to clarify the potential dose- and duration-dependent correlation between cigarette smoking and HLAP. Besides, expanding the number of cases and long-term follow-up are needed.

## REFERENCES

- Whitcomb DC. Clinical practice. Acute pancreatitis. *N Engl J Med* 2006; **354**: 2142-2150 [PMID: 16707751 DOI: 10.1056/NEJMcp054958]
- Chang MC, Su CH, Sun MS, Huang SC, Chiu CT, Chen MC, Lee KT, Lin CC, Lin JT. Etiology of acute pancreatitis--a multi-center study in Taiwan. *Hepatogastroenterology* 2003; **50**: 1655-1657 [PMID: 14571809]
- Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013; **144**: 1252-1261 [PMID: 23622135 DOI: 10.1053/j.gastro.2013.01.068]
- Yin G, Cang X, Yu G, Hu G, Ni J, Xiong J, Hu Y, Xing M, Chen C, Huang Y, Tang M, Zhao Y, Cheng G, Wan R, Wang S, Wang X. Different Clinical Presentations of Hyperlipidemic Acute Pancreatitis: A Retrospective Study. *Pancreas* 2015; **44**: 1105-1110 [PMID: 26348469 DOI: 10.1097/MPA.0000000000000403]
- Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. *Eur J Intern Med* 2014; **25**: 689-694 [PMID: 25269432 DOI: 10.1016/j.ejim.2014.08.008]
- Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. *Eur J Obstet Gynecol Reprod Biol* 2011; **159**: 261-266 [PMID: 21840110 DOI: 10.1016/j.ejogrb.2011.07.037]
- Qiu L, Sun RQ, Jia RR, Ma XY, Cheng L, Tang MC, Zhao Y. Comparison of Existing Clinical Scoring Systems in Predicting Severity and Prognoses of Hyperlipidemic Acute Pancreatitis in Chinese Patients: A Retrospective Study. *Medicine (Baltimore)* 2015; **94**: e957 [PMID: 26061329 DOI: 10.1097/MD.0000000000000957]
- Law R, Parsi M, Lopez R, Zuccaro G, Stevens T. Cigarette smoking is independently associated with chronic pancreatitis. *Pancreatology* 2010; **10**: 54-59 [PMID: 20332662 DOI: 10.1159/000225927]
- Rebours V, Vullierme MP, Hentic O, Maire F, Hammel P, Ruszniewski P, Lévy P. Smoking and the course of recurrent acute and chronic alcoholic pancreatitis: a dose-dependent relationship. *Pancreas* 2012; **41**: 1219-1224 [PMID: 23086245 DOI: 10.1097/MPA.0b013e31825de97d]
- Maisonneuve P, Lowenfels AB, Müllhaupt B, Cavallini G, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L, Frulloni L, Ammann RW. Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. *Gut* 2005; **54**: 510-514 [PMID: 15753536 DOI: 10.1136/gut.2004.039263]
- Sadr-Azodi O, Andrén-Sandberg Å, Orsini N, Wolk A. Cigarette smoking, smoking cessation and acute pancreatitis: a prospective population-based study. *Gut* 2012; **61**: 262-267 [PMID: 21836026 DOI: 10.1136/gutjnl-2011-300566]
- Setiawan VW, Pandol SJ, Porcel J, Wilkens LR, Le Marchand L, Pike MC, Monroe KR. Prospective Study of Alcohol Drinking, Smoking, and Pancreatitis: The Multiethnic Cohort. *Pancreas* 2016; **45**: 819-825 [PMID: 27171516 DOI: 10.1097/MPA.0000000000000657]
- Chowdhury P, Walker A. A cell-based approach to study changes in the pancreas following nicotine exposure in an animal model of injury. *Langenbecks Arch Surg* 2008; **393**: 547-555 [PMID: 18204935 DOI: 10.1007/s00423-007-0267-1]
- Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013; **62**: 102-111 [PMID: 23100216 DOI: 10.1136/gutjnl-2012-302779]
- Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, Liu CJ, Lin CL, Yu MW. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. *Int J Cancer* 2012; **131**: 2612-2621 [PMID: 22362517 DOI: 10.1002/ijc.27508]
- Zhang XF, Wei T, Liu XM, Liu C, Lv Y. Impact of cigarette smoking on outcome of hepatocellular carcinoma after surgery in patients with hepatitis B. *PLoS One* 2014; **9**: e85077 [PMID: 24454795 DOI: 10.1371/journal.pone.0085077]
- Di Leo M, Leandro G, Singh SK, Mariani A, Bianco M, Zuppardo RA, Goni E, Rogger TM, Di Mario F, Guslandi M, De Cobelli F, Del Maschio A, Testoni PA, Cavestro GM. Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis. *Pancreas* 2017; **46**: 225-229 [PMID: 27846144 DOI: 10.1097/MPA.0000000000000737]
- Yin G, Hu G, Cang X, Yu G, Hu Y, Xing M, Chen C, Huang Y, Tang M, Zhao Y, Cheng G, Wan R, Wang X. C-reactive protein: rethinking its role in evaluating the severity of hyperlipidemic acute pancreatitis. *Pancreas* 2014; **43**: 1323-1328 [PMID: 25083999 DOI: 10.1097/MPA.0000000000000187]
- Sun X, Huang X, Zhao R, Chen B, Xie Q. Meta-analysis: Tobacco smoking may enhance the risk of acute pancreatitis. *Pancreatol* 2015; **15**: 286-294 [PMID: 25804129 DOI: 10.1016/j.pan.2015.03.001]
- Coté GA, Yadav D, Slivka A, Hawes RH, Anderson MA, Burton FR, Brand RE, Banks PA, Lewis MD, Disario JA, Gardner TB, Gelrud A, Amann ST, Baillie J, Money ME, O'Connell M, Whitcomb DC, Sherman S; North American Pancreatitis Study Group. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol* 2011; **9**: 266-273; quiz e27 [PMID: 21029787 DOI: 10.1016/j.cgh.2010.10.015]
- Morton C, Klatsky AL, Udaltsova N. Smoking, coffee, and pancreatitis. *Am J Gastroenterol* 2004; **99**: 731-738 [PMID: 15089909 DOI: 10.1111/j.1572-0241.2004.04143.x]
- Lindkvist B, Appelros S, Manjer J, Berglund G, Borgstrom A. A prospective cohort study of smoking in acute pancreatitis. *Pancreatol* 2008; **8**: 63-70 [PMID: 18235217 DOI: 10.1159/000114868]
- Munigala S, Conwell DL, Gelrud A, Agarwal B. Heavy Smoking Is Associated With Lower Age at First Episode of Acute Pancreatitis and a Higher Risk of Recurrence. *Pancreas* 2015; **44**: 876-881 [PMID: 25906444 DOI: 10.1097/MPA.0000000000000364]
- Kristiansen L, Grønbaek M, Becker U, Tolstrup JS. Risk of pancreatitis according to alcohol drinking habits: a population-based cohort study. *Am J Epidemiol* 2008; **168**: 932-937 [PMID: 18779386 DOI: 10.1093/aje/kwn222]
- Yadav D, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA, Bishop MD, Baillie J, Sherman S, DiSario J, Burton FR, Gardner TB, Amann ST, Gelrud A, Lawrence C, Elinoff B, Greer JB, O'Connell M, Barmada MM, Slivka A, Whitcomb DC; North American Pancreatic Study Group. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis.

*Arch Intern Med* 2009; **169**: 1035-1045 [PMID: 19506173 DOI: 10.1001/archinternmed.2009.125]

- 26 **Chowdhury P**, Bose C, Udupa KB. Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signalling and function. *Cell Prolif* 2007; **40**: 125-141 [PMID: 17227300 DOI:

10.1111/j.1365-2184.2007.00418.x]

- 27 **Greer JB**, Thrower E, Yadav D. Epidemiologic and Mechanistic Associations Between Smoking and Pancreatitis. *Curr Treat Options Gastroenterol* 2015; **13**: 332-346 [PMID: 26109145 DOI: 10.1007/s11938-015-0056-9]

**P- Reviewer:** Bradley EL, Gonzalez-Ojeda AG **S- Editor:** Chen K  
**L- Editor:** Wang TQ **E- Editor:** Huang Y







Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

